FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumor

On July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib for adult and pediatric patients at least a year old, with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors. 

For more information, read the FDA announcement. 

Posted 7/19/2022